Industry perspective. Dr Bill Shingleton, GE Healthcare, CT-TRACS Co-Chair, UK

Transcription

1 Industry perspective Dr Bill Shingleton, GE Healthcare, CT-TRACS Co-Chair, UK

2 Tools for Cell Therapy Translation. A Tool-Provider s Perspective. Bill Shingleton GE Healthcare Life Sciences 16 February 2018 Placeholder confidentiality disclosure. Edit or delete from layout master if not needed. Use this second line if additional confidentiality disclosure information is required.

3 GE: A HERITAGE OF INNOVATION Founded by Thomas Edison in 1878 Only company from the original 1896 Dow Jones index still listed today Rated AA+ with stable outlook by S&P 305,000 employees world-wide operating in more than 160 countries

4 GE TODAY ENERGY Energy Services Oil & Gas Power & Water HEALTHCARE AV I AT I O N TRANSPORTATIO N HOME & BUSINESS, SOLUTIONS,

5 THIS IS GE HEALTHCARE An overview

6 BROAD SOLUTIONS FOR HEALTHCARE Diagnostic and Interventional Imaging Patient Monitoring Maternal and Infant Care Anesthesia and Respiratory Care Diagnostic Cardiology Healthcare IT Life Sciences Healthcare Consulting Global Services

7 Single Photon Emission Computed Tomography (SPECT) Positron Emission Tomography (PET) Ultrasound Magnetic Resonance Imaging Computed Tomography (X-ray) Title or Job Number XX Month 201X 7

8 GE Healthcare, Life Sciences Accelerating precision medicine with tools for biotechnology R&D, biopharma manufacturing, cell therapy & regenerative medicine, diagnostic imaging, molecular & precision diagnostics Core Imaging BioProcess Purification & Analysis Cell Therapy Genome & Cellular Research Five product business units people 100+ countries Manufacturing, research & development in US, Europe and Asia

9 Core Imaging Portfolio breadth across three segments Technologies of interest. Contrast Media SPECT PET Further application of ultrasound contrast media therapy delivery & neurology Organ/disease specific MR contrast (e.g. liver) Functional / targeted MR imaging Late stage (lead candidate & P1+) SPECT imaging agents neurodegeneration / general oncology / infection & inflammation areas Late stage (lead candidate & P1+) PET imaging agents in neurodegeneration area Technology enablers Adjacent in vitro diagnostic products for patient selection / stratification Image analysis software (all modalities) Integrated workflow solutions (e.g. dose management / dose delivery / protocols) Imaging tools related to regenerative medicine (e.g. cell therapy) including in

10 GE Healthcare Life Science, Core Imaging Technology areas Contrast agent and tracer development and supply for SPECT / PET / US / MR / X-ray CT Clinical utility Target selection Bio/chem developm t Pre-clinical Process validaton PoC in man Clinical trials Product approval External R&D partnership Internal development Wing-to-wing imaging Contrast / tracer supply - global footprint PET tracer synthesizer units (FASTlab ) Image analysis software Technical support

11 Drug/Agent Development Pathway Idea Molecule synthesis Pre-clinical Manufacture Clinical Trials Launch Safety, DMPK, ADME, MoA, Efficacy &

12 Tools from Core Imaging to Support Cell Therapy Isolate and Enrich Modify Expand Harvest Formulate Quality Check & Release Store & Distribute Administer Elutriation DGM Xuri Activation Viral transduction Transfection Media Growth factors Bioreactors Centrifugation TFF Cytomate KSep Fill and Finish Comparability Safety Identity Purity Potency Cold chain Custody RFID tracking Cryochain Cell monitoring In-vivo imaging Regenerative medicine and stem cell clinical trials: Tracers to potentially monitor cell therapy efficacy: Cell Tracking PD Heart disease AD

13 Ceretec WBC imaging in infection Uptake to Secretory glands e.g. Nasal cavity Tear ducts Salivary glands Courtesy Birmingham City Hospital

14 Tools from Core Imaging to Support Cell Therapy Isolate and Enrich Modify Expand Harvest Formulate Quality Check & Release Store & Distribute Administer Elutriation DGM Xuri Activation Viral transduction Transfection Media Growth factors Bioreactors Centrifugation TFF Cytomate KSep Fill and Finish Comparability Safety Identity Purity Potency Cold chain Custody RFID tracking Cryochain Cell monitoring In-vivo imaging Regenerative medicine and stem cell clinical trials: Tracers to potentially monitor cell therapy efficacy: Cell Tracking PD Heart disease AD

15 Rat Model of Parkinson s Disease L Edit Presentation Title in [Insert Tab > Header & Footer] 16 February

16 Healthcare is evolving to a collaborative care model Current Hospital-centric Model Collaborative Care Model Hospital centric Care Pathways Episodic Patient Centric Solutions Hospital Departments Proprietary Data silos Open Patients Patient data consolidation Interoperable Fee-for-Service Outcome Driven JB35904US Nov. 2015

17

18 Ceretec WBC imaging in inflammation Normal Spleen Lung Appendix abscess Inflammatory bowel disease 1 h pi 45 min pi Courtesy Birmingham City Hospital Bladder 3 h pi

19 Talk Skeleton Introduction to GE, GE Healthcare and GE s Cell Therapy business Why is GE interested in Cell Therapy Bioprocess legacy What is GE s product focus Why does the work of HESI CT-TRACS matter to tool manufacturers and suppliers. Commercialisation of tools and technology for cell therapy translation, aligned of HESI CT-TRACS. The continuum of cell characterisation and in-vivo tracking. How can technology companies help with tool development? GE s customer s un-met needs that are aligned to HESI CT-TRACS. Summary and Discussion. Edit Presentation Title in [Insert Tab > Header & Footer] 16 February